middle.news
Control Bionics begins turning its neurotechnology pipeline into revenue
8:16am on Thursday 29th of October, 2026 AEDT
•
Medical Technology
Read Story
Control Bionics begins turning its neurotechnology pipeline into revenue
8:16am on Thursday 29th of October, 2026 AEDT
Key Points
$5.8 million cash at 30 September after $9.75 million capital raising
First NextLevel OMNI revenue recognised in September following Medicare PDAC approval
NeuroStrip trials more than doubled, with four paying customers
Management forecasts 50% FY27 revenue growth and no further raise before cash flow breakeven
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Control Bionics (ASX:CBL)
OPEN ARTICLE